valproic acid has been researched along with Blood Poisoning in 8 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sepsis is a leading cause of death and disability worldwide." | 5.51 | Valproic acid attenuates sepsis-induced myocardial dysfunction in rats by accelerating autophagy through the PTEN/AKT/mTOR pathway. ( Liu, Y; Shi, X; Xiao, D; Zhang, D, 2019) |
| "Valproic acid (VPA) has been shown to exert anti-inflammatory and antioxidant effects in a range of diseases including septic shock." | 5.39 | Valproic acid attenuates lipopolysaccharide-induced acute lung injury in mice. ( Fan, YX; Gao, DP; Ji, MH; Jia, M; Li, GM; Wu, J; Yang, JJ; Zhu, SH, 2013) |
| " We investigated for the first time whether class I histone deacetylase inhibitor valproic acid (VPA) can reverse cognitive deficits in a mouse model of sepsis-associated encephalopathy (SAE)." | 3.79 | Class I histone deacetylase inhibitor valproic acid reverses cognitive deficits in a mouse model of septic encephalopathy. ( Dong, L; Ji, M; Jia, M; Qiu, L; Wu, J; Yang, J; Zhang, G; Zhang, M, 2013) |
| "Sepsis is a leading cause of death and disability worldwide." | 1.51 | Valproic acid attenuates sepsis-induced myocardial dysfunction in rats by accelerating autophagy through the PTEN/AKT/mTOR pathway. ( Liu, Y; Shi, X; Xiao, D; Zhang, D, 2019) |
| "Valproic acid (VPA) has been shown to exert anti-inflammatory and antioxidant effects in a range of diseases including septic shock." | 1.39 | Valproic acid attenuates lipopolysaccharide-induced acute lung injury in mice. ( Fan, YX; Gao, DP; Ji, MH; Jia, M; Li, GM; Wu, J; Yang, JJ; Zhu, SH, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 6 (75.00) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| De Fazio, C | 1 |
| Goffin, M | 1 |
| Franchi, F | 1 |
| Ferlini, L | 1 |
| Orinckx, C | 1 |
| Spadaro, S | 1 |
| Brasseur, A | 1 |
| Gaspard, N | 1 |
| Antonucci, E | 1 |
| Khattar, L | 1 |
| Peluso, L | 1 |
| Romeo, I | 1 |
| Creteur, J | 1 |
| Legros, B | 1 |
| Taccone, FS | 1 |
| Shi, X | 1 |
| Liu, Y | 1 |
| Zhang, D | 1 |
| Xiao, D | 1 |
| Amathieu, R | 1 |
| Levesque, E | 1 |
| Merle, JC | 1 |
| Chemit, M | 1 |
| Costentin, C | 1 |
| Compagnon, P | 1 |
| Dhonneur, G | 1 |
| Ji, MH | 1 |
| Li, GM | 1 |
| Jia, M | 2 |
| Zhu, SH | 1 |
| Gao, DP | 1 |
| Fan, YX | 1 |
| Wu, J | 2 |
| Yang, JJ | 1 |
| Dong, L | 1 |
| Zhang, M | 1 |
| Zhang, G | 1 |
| Qiu, L | 1 |
| Ji, M | 1 |
| Yang, J | 1 |
| Zheng, Q | 1 |
| Liu, W | 1 |
| Liu, Z | 1 |
| Zhao, H | 1 |
| Han, X | 1 |
| Zhao, M | 1 |
| Qureshi, AU | 1 |
| Abbas, R | 1 |
| Ahmad, TM | 1 |
| Clause, D | 1 |
| Decleire, PY | 1 |
| Vanbinst, R | 1 |
| Soyer, A | 1 |
| Hantson, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Evaluation of Valproic Acid (VPA) as Adjunctive Therapy for Liver Transplant Patients With Moderate to Severe Hemorrhage at Risk of Ischemia Reperfusion (I/R) Injury[NCT04531592] | Phase 2 | 0 participants (Actual) | Interventional | 2022-01-31 | Withdrawn (stopped due to Study terminated by the Sponsor) | ||
| Evaluation of Valproic Acid (VPA) as Adjunctive Therapy for Trauma Patients With Moderate to Severe Hemorrhage at Risk of Ischemia Reperfusion (I/R) Injury[NCT04531579] | Phase 2 | 0 participants (Actual) | Interventional | 2022-01-31 | Withdrawn (stopped due to Study terminated by the Sponsor.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for valproic acid and Blood Poisoning
| Article | Year |
|---|---|
[Severe toxic acute liver failure: etiology and treatment].
Topics: Acetaminophen; Acetylcysteine; Acute Kidney Injury; Anti-Infective Agents; Blood Coagulation Disorde | 2013 |
7 other studies available for valproic acid and Blood Poisoning
| Article | Year |
|---|---|
Hyperammonemia during treatment with valproate in critically ill patients.
Topics: Aged; Critical Care; Critical Illness; Enzyme Inhibitors; Female; Humans; Hyperammonemia; Incidence; | 2022 |
Valproic acid attenuates sepsis-induced myocardial dysfunction in rats by accelerating autophagy through the PTEN/AKT/mTOR pathway.
Topics: Animals; Autophagy; Cecum; Disease Models, Animal; Histone Deacetylase Inhibitors; Histone Deacetyla | 2019 |
Valproic acid attenuates lipopolysaccharide-induced acute lung injury in mice.
Topics: Acute Lung Injury; Animals; Anti-Inflammatory Agents; Antioxidants; Bronchoalveolar Lavage Fluid; Do | 2013 |
Class I histone deacetylase inhibitor valproic acid reverses cognitive deficits in a mouse model of septic encephalopathy.
Topics: Animals; Brain Diseases; Brain-Derived Neurotrophic Factor; Carbazoles; Cecum; Cognition Disorders; | 2013 |
Valproic acid protects septic mice from renal injury by reducing the inflammatory response.
Topics: Acute Kidney Injury; Animals; Cecum; Cyclooxygenase 2; Dinoprostone; Disease Models, Animal; Histone | 2014 |
Valproic acid protects septic mice from renal injury by reducing the inflammatory response.
Topics: Acute Kidney Injury; Animals; Cecum; Cyclooxygenase 2; Dinoprostone; Disease Models, Animal; Histone | 2014 |
Valproic acid protects septic mice from renal injury by reducing the inflammatory response.
Topics: Acute Kidney Injury; Animals; Cecum; Cyclooxygenase 2; Dinoprostone; Disease Models, Animal; Histone | 2014 |
Valproic acid protects septic mice from renal injury by reducing the inflammatory response.
Topics: Acute Kidney Injury; Animals; Cecum; Cyclooxygenase 2; Dinoprostone; Disease Models, Animal; Histone | 2014 |
A case of polyglandular autoimmune syndrome type I with unusual presentation.
Topics: Alcaligenes faecalis; Anti-Bacterial Agents; Anti-Inflammatory Agents; Anticonvulsants; Antifungal A | 2011 |
Pharmacokinetic interaction between valproic acid and meropenem.
Topics: Adult; Aged; Anticonvulsants; Drug Interactions; Humans; Male; Meropenem; Seizures; Sepsis; Thienamy | 2005 |